Myeloproliferative Neoplasm

Oncology·MeSH: Myeloproliferative Disorders

Prevalence

5.0 / 100K

16 drugs in development·8 companies·10 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
eltanexor	Karyopharm Therapeutics Inc. (KPTI)
fedratinib pill	GH Research PLC (GHRS)
inca033989	Incyte Corp. (INCY)
inca035784	Incyte Corp. (INCY)
inca036978	Incyte Corp. (INCY)
JAK Inhibitor	Assertio Holdings, Inc. (ASRT)

Phase 2(7)

Drug	Company
Busulfan	Assertio Holdings, Inc. (ASRT)
Fludarabine	Assertio Holdings, Inc. (ASRT)
incb160058	Incyte Corp. (INCY)
Melphalan	Assertio Holdings, Inc. (ASRT)
Pacritinib	Merus N.V. (MRUS)
Tacrolimus	Assertio Holdings, Inc. (ASRT)
Tacrolimus	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(1)

Drug	Company
standard disease-directed therapy	Incyte Corp. (INCY)

Preclinical(2)

Drug	Company
cpi-482	CONSTELLATION PHARMACEUTICALS INC (CNST)
JAK2 program	Cogent Biosciences, Inc. (COGT)

BioSniper tracks 16 drugs in development for Myeloproliferative Neoplasm across 8 companies.

There are 10 clinical trials targeting Myeloproliferative Neoplasm tracked by BioSniper.

The estimated prevalence of Myeloproliferative Neoplasm is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.